When did Evommune report Q1 2026 earnings?

Evommune (EVMN) reported Q1 2026 earnings on May 7, 2026 before market open.

What were Evommune 's Q1 2026 revenue and EPS?

Evommune reported revenue of $1.6M and diluted EPS of $-0.64 for Q1 2026.

Did Evommune beat estimates in Q1 2026?

Revenue beat the consensus estimate of $722.2K by $923.4K. EPS beat the consensus estimate of $-0.83 by $0.19.

Where can I find Evommune 's Q1 2026 SEC filings?

You can read the 10-Q periodic report (0001213900-26-057934) directly on SEC EDGAR. The filing index links above go to sec.gov.

Evommune EVMN Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$1.6MBeat by $923.4K Diluted EPS-$0.64Beat by $0.19

Revenue estimate$722.2K

EPS estimate-$0.83

Next report

Aug 6, 2026 (in a month)

Revenue estimate$1.3M

EPS estimate-$0.68

Financials

Q1 2026

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

Valuation & ratios

Valuation

as of 06/26/26

See full

Market cap$869.12M—

Enterprise value$870.05M—

P/S130.4×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Returns & leverage

See full

Current ratio1.2×—

Segments

By product

See full

Nutraceuticalsupplements$1.6M+7.8%

Hemp Derived Products$6.3K-91.0%

Versus estimates

Revenue

Q3 2025$10.0MBeat by $6.7M

Diluted EPS

Q1 2026-$0.64Beat by $0.19

Q4 2025-$1.43Miss by $0.61 Q3 2025-$8.07Miss by $1.99

Ask the moment Evommune reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Evommune report Q1 2026 earnings?: Evommune (EVMN) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Evommune 's Q1 2026 revenue and EPS?: Evommune reported revenue of $1.6M and diluted EPS of $-0.64 for Q1 2026.
Did Evommune beat estimates in Q1 2026?: Revenue beat the consensus estimate of $722.2K by $923.4K. EPS beat the consensus estimate of $-0.83 by $0.19.
Where can I find Evommune 's Q1 2026 SEC filings?: You can read the 10-Q periodic report (0001213900-26-057934) directly on SEC EDGAR. The filing index links above go to sec.gov.